— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to ...

Takeda ( TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, ...

Phase 4 DUET enrolled adults with NT1/NT2 or idiopathic hypersomnia (ESS >10) and showed ≥2-point ESS reductions in 82% of narcolepsy and 95% of hypersomnia participants. Normal-range ESS (≤10) was ...

Takeda has presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin ...

Narcolepsy is a chronic neurological sleep disorder that disrupts the brain’s ability to regulate sleep-wake cycles, leading to sudden sleep attacks, fragmented nighttime sleep, and overwhelming ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...

Two new studies to be presented at the SLEEP 2024 annual meeting show that narcolepsy is an independent risk factor for cardiovascular disease and adverse cardiac events. In a separate analysis of the ...

That overwhelming sleepiness dragging you down might not just be from staying up too late scrolling through TikTok. While everyone occasionally battles the afternoon slump, people with hypersomnia or ...

This informational guide, part of POPSUGAR's Condition Center, lays out the realities of this health concern: what it is, what it can look like, and strategies that medical experts say are proven to ...